ERBB2 and breast carcinoma: Another study in the adjuvant setting, the ATEMP trial, aimed to determine whether treatment with T-DM1 had less toxicity than paclitaxel plus trastuzumab and provided a clinically acceptable iDFS in patients with stage I HER2-positive breast cancer.29 The development of TDM-1 as a neoadjuvant therapy has led to variable outcomes.